3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
252
Breast Neoplasms
197
Glioblastoma
196
Lung Neoplasms
195
Head and Neck Neoplasms
176
Squamous Cell Carcinoma of Head and Neck
166
Prostatic Neoplasms
164
Lymphoma
152
Rectal Neoplasms
132
Central Nervous System Neoplasms
119
Esophageal Neoplasms
117
Leukemia
111
Brain Neoplasms
100
Pancreatic Neoplasms
95
Precursor Cell Lymphoblastic Leukemia-Lymphoma
93
Gliosarcoma
86
Esophageal Squamous Cell Carcinoma
83
Lymphoma, Follicular
81
Sarcoma
80
Lymphoma, Large B-Cell, Diffuse
80
Uterine Cervical Neoplasms
76
Lymphoma, Non-Hodgkin
75
Hodgkin Disease
73
Neoplasms
68
Burkitt Lymphoma
67
Leukemia, Lymphocytic, Chronic, B-Cell
63
Colorectal Neoplasms
63
Glioma
61
Astrocytoma
60
Lymphoma, Large-Cell, Immunoblastic
58
Interventions
Vincristine
2
Temozolomide
2
Oncolytic Virotherapy
2
repotrectinib
1
pralsetinib
1
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
cixutumumab
1
Vorinostat
1
Valproic Acid
1
Thiotepa
1
Sunitinib
1
Radiotherapy
1
Radiation
1
Peripheral Blood Stem Cell Transplantation
1
ONC206
1
Melphalan
1
Maintenance Chemotherapy
1
Lomustine
1
Interleukin-12
1
Interferon-gamma
1
Immunotherapy
1
Granulocyte Colony-Stimulating Factor
1
Filgrastim
1
Etoposide
1
Erlotinib Hydrochloride
1
Doxorubicin
1
Cyclophosphamide
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neuroectodermal Tumors
×
Radiotherapy
×
Clear all
NCT01614132
2020-03-31
NOA-07
University of Regensburg
Phase 1/2
Completed
33 enrolled